Alpha Teknova Inc TKNO

$8.99 +0.13 (1.47%)

Valuation

Market cap
475,020,000
Revenue TTM
$40,520,000
Net income TTM
$-17,260,000
PE ratio
0.00
Forward PE
—
Profit margin
-42.60%
Debt to equity
0.21

Trading

Volume
249,300
Avg volume
246,988
Day's range
$8.80 – $9.04
Shares out
53,614,000
Stochastic %K
59%
Beta
0.85
Analysts
Strong Sell
Price target
$9.00

Price

Company profile

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, res...

Show more

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
831 637 1100
Website
https://www.teknova.com
Address
2451 Bert Dr., Hollister, United States

Latest news

No headlines yet.